Table 3.
MRSA cSSTI clinical outcomes
| Outcome | Overall (N=87) |
Saudi Arabia (N=49) |
Lebanon (N=38) |
|---|---|---|---|
| Clinical response at discharge | |||
| Curea | 44% | 47% | 39% |
| Improvementb | 33% | 20% | 50% |
| Failurec | 7% | 8% | 5% |
| Indeterminated | 16% | 24% | 5% |
| Outcomes 30-days postdischargee | |||
| Relapse of MRSA cSSTI | 6% | 7% | 5% |
| Rehospitalization for MRSA cSSTI | 4% | 5% | 3% |
| Rehospitalization, any reason | 14% | 7% | 22% |
Note:
a
Resolution of all signs and symptoms/improvement to such an extent that further antimicrobial therapy was not necessary.
b
Improvement in signs and symptoms.
c
Persistence, incomplete clinical resolution, or worsening in signs and symptoms.
d
Inability to determine an outcome.
e
Postdischarge outcomes only measured in patients who survived to discharge (80 overall, 43 Saudi Arabia, 37 Lebanon).
Abbreviations: cSSTI, complicated skin and soft tissue infections; MRSA, methicillin-resistant Staphylococcus aureus.